The SYMPLICITY HTN-3 trial, a phase 3 study testing catheter-based renal denervation for the treatment of resistant hypertension, failed to achieve its primary efficacy end point, according to a statement released by Medtronic[1].
[Ссылки доступны только зарегистрированным пользователям ]
14.01.2014, 12:29
Древовидный вид